Trial · NCT01704196

A Multi-Center Trial of Nepicastat for Cocaine Dependence

NCT01704196, Phase 2, Completed, National Institute on Drug Abuse (NIDA); results first posted 2017-05-18

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. A Multi-Center Trial of Nepicastat for Cocaine Dependence. Trials, record NCT01704196. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01704196

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: A Multi-Center Trial of Nepicastat for Cocaine Dependence
NCT number: NCT01704196
Status: Completed
Phases: Phase 2
Enrollment: 179 participants, actual
Lead sponsor: National Institute on Drug Abuse (NIDA)
Conditions: Cocaine Dependence
Interventions: Nepicastat, Placebo
First posted: 2012-10-11
Last updated: 2017-05-18
Results first posted: 2017-05-18

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Abstinence (Weeks 10 - 11)	Weeks 10 - 11	Number of subjects that abstained from cocaine from weeks 10 through 11
Secondary	Reduction in Use (Weeks 1 - 11)	Baseline through week 11	Proportion of Subjects with a 50% or More Reduction in Cocaine Use from Baseline through week 11

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Abstinence (Weeks 10 - 11)	Weeks 10 - 11		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Reduction in Use (Weeks 1 - 11)	Baseline through week 11		participants	NUMBER

Source ClinicalTrials.gov

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Units
Abstinence (Weeks 10 - 11)	Nepicastat	4	Participants
Abstinence (Weeks 10 - 11)	Placebo	7	Participants
Reduction in Use (Weeks 1 - 11)	Nepicastat	13	participants
Reduction in Use (Weeks 1 - 11)	Placebo	20	participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Nepicastat	90
Overall Study	STARTED	Placebo	89
Overall Study	COMPLETED	Nepicastat	71
Overall Study	COMPLETED	Placebo	65
Overall Study	NOT COMPLETED	Nepicastat	19
Overall Study	NOT COMPLETED	Placebo	24

Source ClinicalTrials.gov

Adverse events52

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Diarrhea	Gastrointestinal disorders	Nepicastat	6	90	6
other	Diarrhea	Gastrointestinal disorders	Placebo	7	89	10
other	Nausea	Gastrointestinal disorders	Nepicastat	6	90	7
other	Nausea	Gastrointestinal disorders	Placebo	5	89	5
other	Headache	Nervous system disorders	Nepicastat	16	90	20
other	Headache	Nervous system disorders	Placebo	11	89	17
other	Rash	Skin and subcutaneous tissue disorders	Nepicastat	7	90	8
other	Rash	Skin and subcutaneous tissue disorders	Placebo	2	89	2
other	Hypertension	Vascular disorders	Nepicastat	6	90	9
other	Hypertension	Vascular disorders	Placebo	7	89	9

1 to 10 of 52Source ClinicalTrials.gov

See all 52 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Nepicastat
Total, all-cause mortality	Placebo
Total, other adverse events	Nepicastat	80	90
Total, other adverse events	Placebo	67	89
Total, serious adverse events	Nepicastat	8	90
Total, serious adverse events	Placebo	2	89

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons3

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Nepicastat vs Placebo: Reduction in Use (Weeks 1 - 11)	Trial comparisons
Nepicastat vs Placebo: Abstinence (Weeks 10 - 11)	Trial comparisons
Nepicastat vs Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01704196

GET https://conductscience.org/api/trials/v1/NCT01704196/events?page=2

API reference For AI assistants